Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

In this issue of The Lancet Diabetes & Endocrinology, Michelle M Chen and colleagues1 report their findings on trends in the incidence of thyroid cancer in the USA from 1975 to 2019. The authors show ...

Despite efforts to curb overdiagnosis of thyroid cancer, the issue has continued to plague U.S. healthcare, according to results from a retrospective, population-based study.

While doctors haven’t pinpointed exact causes, certain factors significantly increase your chances of developing thyroid cancer. Women face three times higher risk than men, particularly between ...

such as thyroid cancer. The discovery of these alarming signs may often save lives because early detection becomes the first objective of treatment. Here are seven signs that suggest a thyroid may ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

Around 9 in 10 (91.4%) of people diagnosed with thyroid cancer in England survive their disease for one year or more (2013-2017). Almost 9 in 10 (87.4%) of people diagnosed with thyroid cancer in ...

The leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. GLP1-Ras are incretin-based ...

In the largest study of its kind involving a diabetic population, the use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) drugs shows no significantly increased risk for thyroid cancer ...

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.

Doctors say thyroid cancer occurs in women at a much higher ... But I would later be grateful that it was caught early, because that discovery led to other medical testing. It’s during those ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...